阿狄科®犬尿氨酸高灵敏检测试剂盒（酶联免疫法）

【产品名称】
通用名称：犬尿氨酸高灵敏检测试剂盒（酶联免疫法）
英文名称：Kynurenine high sensitive (IDK® Kynurenine high sensitive) ELISA

【包装规格】
规格：96人份（复孔检测样本：40个）/盒
测试次数：96（40份样本一式两份）

【预期用途】
犬尿氨酸高灵敏检测试剂盒（酶联免疫法）用于体外定量测定啮齿动物血浆、血清、脑组织、细胞培养上清液和CSF( 脑脊液)中的L-犬尿氨酸。仅供科研使用。

【产品相关】
孵育时间: 45分钟+5分钟+1小时+10分钟
样本量: 10µl
样本类型: 血浆，血清，脑组织（小鼠/大鼠）,细胞培养上清液, CSF( 脑脊液)
标准品：0.04-10µmol/l
用于检测人血浆、血清和尿液样本时，推荐采用IDK®Kynurenine ELISA（货号 K 7728）。

【背景知识】

• 犬尿氨酸是人体必需氨基酸色色氨酸的代谢产物之一,是一种具有多种特殊生理作用的生物活性分子,犬尿氨酸及其代谢产物与多种神经精神疾病、肾功能衰竭、白内障、各种慢性恶性疾病等密切相关。
• 因此，定量测定机体Kynurenine对相关疾病的诊断治疗、疗效监测及发病机制等研究具有重要参考价值。
• 慢性肾功能衰竭患者（CRF）患者外周血存在较为严重的犬尿氨酸代谢紊乱,且与肾功能水平及CRF的某些临床症状密切相关。（来源：李江.慢性肾功能衰竭患者血清色氨酸和犬尿氨酸检测及其临床意义. 《中华医学会第七次全国检验医学学术会议资料汇编》2008年.）
• 丹娜法伯癌症研究所肿瘤专家、哈佛医学院医学助理教授Giannakis说：“在接受纳武利尤单抗治疗的大多数患者中，我们发现犬尿氨酸的水平升高。这种物质被认为具有免疫抑制作用。”
• 在黑色素瘤患者中，第4周时，78%的患者色氨酸-犬尿氨酸转化率增加，26.5%的患者增加比例超过50%。在肾癌患者中，纳武利尤单抗的治疗效果也与犬尿氨酸增加有关。
• 分析表明，黑色素瘤和肾癌患者在接受纳武利尤单抗治疗后色氨酸-犬尿氨酸转化率增加，与较低的生存率有关。具体来说，血液检测显示转换率在50%以上的黑色素瘤患者，中位生存期只有15.7个月，而低于这一比例的患者中位生存期超过39个月。肾癌患者中位生存期分别为16.7个月和31.3个月。

参考文献
1. Cavia-Saiz M, Muniz Rodriguez P, Llorente Ayala B, Garcia-Gonzalez M, Coma-Del Corral MJ, Garcia Giron C. The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer. Mol Biol Rep. 2014 Apr; 41(4):2275-9.
2. Chuang SC, Fanidi A, Ueland PM et al: Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2014 Mar; 23(3):461-8 Manual IDKR Kynurenine high sensitive ELISA 29
3. Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR, Soliman HH: Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III nonsmall cell lung cancer. Oncoimmunology. 2013 Mar 1; 2(3):e23428
4. Eussen S J PM, Ueland P M, Vollset S E, Nygard O, Midttun O, Sulo G,Tell GS: Kynurenines as predictors of acute coronary events in the Hordaland Health Study. Int J Cardiol. 2015 Jun 15;189:18-24
5. Gupta NK, Thaker AI, Kanuri N, Riehl TE, Rowley CW, Stenson WF, Ciorba MA: Serum analysis of tryptophan catabolism pathway: correlation with Crohn's disease activity. Inflamm Bowel Dis. 2012 Jul; 18(7):1214-20.
6. Murray C, Griffin EW, O’Loughlin E, Lyons A, Sherwin E, Ahmed S, Stevenson N J, et al. Interdependent and independent roles of type I interferons and IL-6 in innate immune, neuroinflammatory and sickness behaviour responses to systemic poly I:C. Brain, Behavior, and Immunity. 2015, 48: 274-286.
7. Pedersen ER, Svingen GF, Schartum-Hansen H, Ueland PM, Ebbing M, Nordrehaug JE, Igland J, Seifert R, Nilsen RM, Nygard O: Urinary excretion of kynurenine and tryptophan, cardiovascular events, and mortality after elective coronary angiography. Eur Heart J. 2013 Sep; 34(34):2689-96.
8. Ristagno G, Latini R, Vaahersalo J, Masson S, Kurola J, Varpula T, Lucchetti J, Fracasso C, Guiso G, Montanelli A, Barlera S, Gobbi M, Tiainen M, Pettila V, Skrifvars MB; FINNRESUSCI Investigators: Early activation of the kynurenine pathway predicts early death and long-term outcome in patients resuscitated from out-of-hospital cardiac arrest. J Am Heart Assoc. 2014; 3:e001094
9. Sulo G, Vollset SE, Nygard O, Midttun O, Ueland PM, Eussen SJ, Pedersen ER, Tell GS: Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study. Int J Cardiol. 2013 Sep 30; 168(2):1435-40
10. Suzuki Y, Suda T, Asada K, Miwa S, Suzuki M, Fujie M, Furuhashi K, Nakamura Y, Inui N, Shirai T, Hayakawa H, Nakamura H, Chida K: Serum Indoleamine 2,3- Dioxygenase Activity Predicts Prognosis of Pulmonary Tuberculosis. Clin Vaccine Immunol. 2012 March; 19(3): 436–442
11. Yan EB, Frugier T, Lim CK, Heng B, Sundaram G, Tan M, Rosenfeld JV, et al. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans. Journal of Neuroinflammation. 2015,12(1), 110.